What's next in cancer immunotherapy?-The promise and challenges of neoantigen vaccination

被引：8
|
作者：
Redwood, Alec J. [1 ,2 ]
Dick, Ian M. [1 ,2 ,3 ]
Creaney, Jenette [1 ,2 ,3 ,4 ]
Robinson, Bruce W. S. [1 ,2 ,4 ,5 ]
机构：
[1] Univ Western Australia, Inst Resp Hlth, Perth, WA, Australia
[2] Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA, Australia
[3] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia
[4] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA, Australia
[5] Univ Western Australia, Med Sch, Perth, WA, Australia
来源：
ONCOIMMUNOLOGY | 2022年 / 11卷 / 01期
基金：
英国医学研究理事会;
关键词：
Neoantigen; immunotherapy; vaccine; neoantigen vaccine; CYTOTOXIC T-LYMPHOCYTES; MHC CLASS-I; COLORECTAL CANCERS; CELL IMMUNITY; LUNG-CANCER; BLOCKADE; ANTIGEN; CD8; RESPONSES; PEPTIDES;
D O I：
10.1080/2162402X.2022.2038403
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The process of tumorigenesis leaves a series of indelible genetic changes in tumor cells, that when expressed, have the potential to be tumor-specific immune targets. Neoantigen vaccines that capitalize on this potential immunogenicity have shown efficacy in preclinical models and have now entered clinical trials. Here we discuss the status of personalized neoantigen vaccines and the current major challenges to this nascent field. In particular, we focus on the types of antigens that can be targeted by vaccination and on the role that preexisting immunosuppression, and in particular T-cell exhaustion, will play in the development of effective cancer vaccines.
引用
收藏
页数：12
相关论文
共 50 条
  • [21] Immunotherapy in Breast Cancer: When, How, and What Challenges?
    Henriques, Beatriz
    Mendes, Fernando
    Martins, Diana
    BIOMEDICINES, 2021, 9 (11)
  • [22] Challenges in the combination of radiotherapy and immunotherapy for breast cancer
    Zhang, Rui
    Clark, Samantha D.
    Guod, Beibei
    Zhang, Tianyi
    Jeansonne, Duane
    Jeyaseelan, Samithamby J.
    Francis, Joseph
    Huang, Weishan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (04) : 375 - 383
  • [23] Pancreatic cancer - What's next?
    Salvia, Roberto
    Casciani, Fabio
    Sereni, Elisabetta
    Bassi, Claudio
    PRESSE MEDICALE, 2019, 48 (03): : E187 - E197
  • [24] Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer
    Madan, Ravi A.
    Gulley, James L.
    IMMUNOTHERAPY, 2011, 3 (01) : 27 - 31
  • [25] Cancer vaccines: the next immunotherapy frontier
    Lin, Matthew J.
    Svensson-Arvelund, Judit
    Lubitz, Gabrielle S.
    Marabelle, Aurelien
    Melero, Ignacio
    Brown, Brian D.
    Brody, Joshua D.
    NATURE CANCER, 2022, 3 (08) : 911 - 926
  • [26] Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land
    Yu, Ganjun
    He, Xiaobo
    Li, Xing
    Wu, Yanfeng
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 153
  • [27] Immunotherapy for prostate cancer: recent developments and future challenges
    Schweizer, Michael T.
    Drake, Charles G.
    CANCER AND METASTASIS REVIEWS, 2014, 33 (2-3) : 641 - 655
  • [28] Probiotic neoantigen delivery vectors for precision cancer immunotherapy
    Redenti, Andrew
    Im, Jongwon
    Redenti, Benjamin
    Li, Fangda
    Rouanne, Mathieu
    Sheng, Zeren
    Sun, William
    Gurbatri, Candice R.
    Huang, Shunyu
    Komaranchath, Meghna
    Jang, Younguk
    Hahn, Jaeseung
    Ballister, Edward R.
    Vincent, Rosa L.
    Vardoshivilli, Ana
    Danino, Tal
    Arpaia, Nicholas
    NATURE, 2024, 635 (8038) : 453 - 461
  • [29] Harnessing neoantigen specific CD4 T cells for cancer immunotherapy
    Brightman, Spencer E.
    Naradikian, Martin S.
    Miller, Aaron M.
    Schoenberger, Stephen P.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2020, 107 (04) : 625 - 633
  • [30] Personalized vaccination against ovarian cancer: what are the possibilities?
    Tanyi, Janos L.
    George, Erin
    EXPERT REVIEW OF VACCINES, 2018, 17 (11) : 955 - 958
12345